Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin

Thrombosis Research

Volumn 127, Issue 6, 2011, Pages 603-604

  Inoue, Yasuyuki ^a   Kosugi, Shigeki ^b   Miura, Ikuo ^b   Hatta, Yoshihiro ^a   Takeuchi, Jin ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; FIBRINOGEN DEGRADATION PRODUCT; HAPTOGLOBIN; HIGH MOBILITY GROUP B1 PROTEIN; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; RECOMBINANT THROMBOMODULIN;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CASE REPORT; COLON BIOPSY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINAL TRANSPLANT ASSOCIATED MICROANGIOPATHY; LETTER; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ACUTE DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOMODULIN; THROMBOTIC MICROANGIOPATHIES;

EID: 79957597281     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.12.023     Document Type: Letter

References (8)

1. Iwamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohono A, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant 2009;44:43-9.
2. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41. (Pubitemid 44921064)
3. Abeyama K, DStren M, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005;115:1267-74. (Pubitemid 40629045)
4. Nagato M, Okamoto K, Abe Y, Higure A, Yamaguchi K. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009;37:2181-6.
5. Ombrellino M, Wang H, Ajemian MS, Talhouk A, Scher AL, Friedman GS. Tracy KJ Increased serum concentrations of high-mobility group protein 1 in haemorrhagic shock. Lancet 1999;354:1446-7. (Pubitemid 29494763)
6. Kornblit B, Masnas T, Petersen SL, Madsen HO, Healman C, Schejbel L, et al. Association of HMGB1 Polymorphism with Outcome after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2010;16:239-52.
7. Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Blood Marrow Transpl 2010;45: 783-5.
8. Sakai M, Ikezoe T, Bandobashi K, Togitani K, Yokoyama A. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Blood Marrow Transpl 2010;45:803-5.